Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Event Logistics

- PMLiVE

XenoGesis appoints business development consultant

Sabrina Mogle will spearhead CRO’s US growth

- PMLiVE

AZ withdraws EU filing for ovarian cancer drug cediranib

Maintains cediranib’s value as a combination therapy despite EMA information request

- PMLiVE

Key Accounts

But not as we know it?

Bristol-Myers Squibb (BMS) building

BMS chases after Roche in EU bladder cancer race

Opdivo set to go head-to-head with Tecentriq

- PMLiVE

Allergan buys two NASH drug developers in one day

More than $1.7bn paid for Tobira Therapeutics and Akarna Therapeutics

- PMLiVE

Bedrock appoints new commercial director

Dr Laura Ciccolini brings experience from the Biopharm Group and Sigma Aldrich

- PMLiVE

Adult learning theory

Practical benefits for optimum patient outcomes

- PMLiVE

The UK’s new Cancer Drugs Fund

"Clearer, faster decision-making" promised

- PMLiVE

ROAD Comms wins antimicrobial resistance account

Selected by GAMA Healthcare to create infection control campaign

- PMLiVE

Medical Research Council launches disease compounds research library

Teams up with AZ, GSK, Janssen, Pfizer, Takeda and UCB

- PMLiVE

GSK names Emma Walmsley as next CEO

Firm's consumer healthcare head will succeed Sir Andrew Witty in March 2017

- PMLiVE

Sarepta soars as FDA clears its muscular dystrophy drug

Analysts anticipate blockbuster status for DMD therapy despite efficacy concerns

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links